PepEvolution
Home›Learn›Semaglutide Dosage
Dosing researchPepScore 71 · B →

Semaglutide Dosage: What the Label and Trials Show

Semaglutide · Ozempic / Wegovy

Status & framing. Semaglutide is FDA-approved as Ozempic (type 2 diabetes) and Wegovy (chronic weight management) in branded pens. Research/compounded vials are not the approved products. Figures below cite labeled titration and trial context, not a recommendation to use non-approved products.

What the research shows

Approved pen products use once-weekly subcutaneous titration. Wegovy starts at 0.25 mg weekly for 4 weeks, then steps up toward a 2.4 mg maintenance dose when tolerated. Ozempic uses a related weekly titration path for glycemic control. Human evidence is extensive for the approved products; research vials are a different supply channel.

Doses used in studies

Each row is a dose as reported in the cited source, not a recommendation. Superscripts link to sources below.

ContextDose studiedRoute / frequency
Wegovy label, titration start0.25 mg once weekly for 4 weeks[1]⚠ Approved product dose path. Compounded/research vials are not Wegovy.Subcutaneous (approved pen)
Wegovy label, maintenance target2.4 mg once weekly (when tolerated)[1]Subcutaneous (approved pen)
STEP / obesity trial contextWeekly titration toward 2.4 mg[2]⚠ Trial product and medical supervision context.Subcutaneous

Reconstitution & example math

A 5 mg research vial reconstituted with 2 mL bacteriostatic water yields 2.5 mg/mL. A 0.25 mg (250 mcg) example draw is 0.1 mL, or 10 units on a U-100 syringe. That is an arithmetic example only, not a protocol.

Approved products are pens with fixed dosing. Research vials require independent concentration math and cold-chain handling. Do not treat vial math as a substitute for labeled therapy.

Route, half-life & timing

Class
GLP-1 receptor agonist[1][2]
Typical approved schedule
Once weekly subcutaneous titration[1]
Half-life
Approximately 1 week for the approved molecule (label context)[1]

Safety & side-effect notes from the literature

  • Approved labels carry GI adverse effects, boxed/warning language around thyroid C-cell tumor risk in rodents, and multiple contraindications. Read the current label.[1]
  • Compounded or research-channel products are not the FDA-approved pens and may differ in salt form, impurities, and dosing accuracy.[3]

Frequently asked

What is the starting dose of Wegovy semaglutide?+

The Wegovy label starts at 0.25 mg once weekly for 4 weeks, then titrates upward when tolerated toward a 2.4 mg weekly maintenance dose.

Are research vials the same as Ozempic or Wegovy?+

No. Ozempic and Wegovy are specific approved pen products. Research or compounded vials are a different channel and are not those approved products.

PRO

Get the full Semaglutide protocol

PepEvolution Pro turns these research ranges into a personalized schedule, a full Semaglutide protocol with a week-by-week plan, sourcing shortlist, and COA-checked vendors. Educational, cited, and built on the same methodology.

See what's in Pro →

Sources & Citations

Primary sources only. Doses are stated as reported, see methodology.

  1. [1]FDA, Wegovy (semaglutide) label & approval
  2. [2]STEP program / semaglutide obesity trials (PubMed)
  3. [3]FDA compounding / research peptide context

Related

Educational only, not medical advice. Doses on this page are figures used in published research or clinical labeling, presented for education. They are not a prescription or a recommendation to self-administer. Consult a licensed healthcare provider before using any compound.